Ray Dalio Bridgewater Associates
Ray Dalio is the founder of Bridgewater Associates, one of the world’s largest hedge funds, known for its unique “principles-based” culture and systematic investment approach. Dalio’s investment philosophy emphasizes diversified portfolios, risk parity, and the importance of understanding economic cycles in shaping investment decisions. He has authored several books, including “Principles: Life & Work,” in which he details his management philosophies, personal experiences, and life lessons.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$148M |
| 2 |
Mondelez International
MDLZ
|
+$144M |
| 3 |
Johnson & Johnson
JNJ
|
+$64.3M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$53.4M |
| 5 |
Microsoft
MSFT
|
+$51.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$225M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$151M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$91.6M |
| 4 |
Walmart Inc
WMT
|
+$87.7M |
| 5 |
JPMorgan Chase
JPM
|
+$79.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 29.71% |
| 2 | Healthcare | 20.65% |
| 3 | Consumer Discretionary | 10.85% |
| 4 | Financials | 7.63% |
| 5 | Technology | 4.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Eagle Materials
EXP
$6.57B
| $5.02M | 0.03% |
46,851
+6,339
| +16% | +$759K |
|
377
National Fuel Gas
NFG
$7.65B
| $5.01M | 0.03% |
81,362
+70,078
| +621% | +$4.83M |
|
|
ATVI
378
DELISTED
Activision Blizzard
ATVI
| $4.98M | 0.03% |
66,997
-157,621
| -70% | -$12.3M |
|
|
AMED
379
DELISTED
Amedisys
AMED
| $4.95M | 0.03% |
51,169
-184
| -0.4% | -$21.9K |
|
|
WRK
380
DELISTED
WestRock Company
WRK
| $4.95M | 0.03% |
160,329
-93,416
| -37% | -$3.69M |
|
|
NARI
381
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $4.94M | 0.03% |
67,958
+819
| +1% | +$61K |
|
382
Crocs
CROX
$6.55B
| $4.92M | 0.02% |
71,578
-45,586
| -39% | -$3.16M |
|
383
Integra LifeSciences
IART
$1.34B
| $4.89M | 0.02% |
115,507
+424
| +0.4% | +$21.7K |
|
384
Tandem Diabetes Care
TNDM
$1.56B
| $4.87M | 0.02% |
101,743
+249
| +0.2% | +$13.7K |
|
385
Futu Holdings
FUTU
$15.3B
| $4.85M | 0.02% |
+130,168
| New | +$5.68M |
|
|
CD
386
DELISTED
Chindata Group Holdings Limited American Depositary Shares
CD
| $4.82M | 0.02% |
596,820
-83,188
| -12% | -$641K |
|
387
Sanmina
SANM
$10.9B
| $4.78M | 0.02% |
103,709
-25,161
| -20% | -$1.17M |
|
388
Central Garden & Pet Co Class A
CENTA
$2.44B
| $4.76M | 0.02% |
174,363
-8,126
| -4% | -$255K |
|
389
Goldman Sachs
GS
$303B
| $4.75M | 0.02% |
16,193
-57,580
| -78% | -$18.7M |
|
390
ICU Medical
ICUI
$4.61B
| $4.74M | 0.02% |
+31,466
| New | +$5.24M |
|
391
Glaukos
GKOS
$10.6B
| $4.74M | 0.02% |
88,940
-4,771
| -5% | -$246K |
|
392
Stride
LRN
$3.43B
| $4.73M | 0.02% |
112,533
-4,175
| -4% | -$168K |
|
393
Shake Shack
SHAK
$2.87B
| $4.71M | 0.02% |
104,705
-2,784
| -3% | -$134K |
|
394
Credit Acceptance
CACC
$6.08B
| $4.66M | 0.02% |
10,632
-3,754
| -26% | -$1.98M |
|
395
Allstate
ALL
$67.5B
| $4.65M | 0.02% |
37,355
-130,297
| -78% | -$16.2M |
|
396
Xylem
XYL
$28.1B
| $4.64M | 0.02% |
53,156
-15,385
| -22% | -$1.4M |
|
397
Nu Skin
NUS
$267M
| $4.63M | 0.02% |
138,628
-41,545
| -23% | -$1.73M |
|
398
Owens Corning
OC
$12.4B
| $4.61M | 0.02% |
58,615
-107,455
| -65% | -$9.03M |
|
399
Waters Corp
WAT
$39.9B
| $4.59M | 0.02% |
17,028
+12,204
| +253% | +$3.9M |
|
400
RELX
RELX
$62B
| $4.55M | 0.02% |
187,067
+32,306
| +21% | +$877K |
|
Similar funds
Ray Dalio's Q3 2022 Portfolio in Review
As of Q3 2022, Ray Dalio held 1,045 positions worth $19.8B, down 16% from $23.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Ray Dalio withdrew a net $2.53B in Q3 2022, closing 179 positions and reducing 498 holdings. Its most notable exit was Medtronic, an estimated $225M position sold in full.
By sector, the portfolio is most concentrated in Consumer Staples at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Ray Dalio opened a new position in Accenture worth $29.3M.
- Ray Dalio's largest Q3 2022 buy was Accenture: 113,811 shares worth $29.3M.
- Ray Dalio added most to Visa in Q3 2022, an estimated $148M increase.
- Ray Dalio's biggest Q3 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $151M.
- Ray Dalio fully exited Medtronic in Q3 2022, selling an estimated $225M.
- Ray Dalio's ten largest holdings make up 32% of its $19.8B portfolio in Q3 2022.
- Ray Dalio opened 60 new positions and closed 179 in Q3 2022.
- Ray Dalio's portfolio value fell 16% quarter-over-quarter to $19.8B.
Based on Bridgewater Associates's 13F filing for Q3 2022, filed 10 Nov 2022.